Acquisition of Solus Biotech strengthens Croda Pharma

On 04 July Croda successfully completed the acquisition of Solus Biotech, an innovative biotechnology company with over three decades of industry experience. Based in South Korea, Solus provides us the opportunity to expand our Asian manufacturing capabilities as well as creating a new biotechnology R&D hub in the region.

How will Solus strengthen Croda Pharma?

The acquisition of Solus will enable us to tap into their portfolio of natural phosphatidylcholines from soybean, sunflower and egg lecithin. These pharma grade phospholipids are produced to GMP standards and have applications as emulsifiers and in drug delivery systems (DDS) for pharmaceutical APIs. Formulating DDS with phospholipids provides several advantages including enhanced bioavailability of APIs with low aqueous solubility, reduced toxicity and increased API stability. Solus offers high purity soya phosphatidylcholine for drug-phospholipid complexes in DDS. Additionally, Solus’ phospholipid capabilities will allow for collaborative R&D with our Avanti business, boosting the supply of lipid systems for drug delivery in the future.

As well as expanding our product offering Solus aligns with our commitment to sustainability. Together with their natural phospholipid offering Solus is developing biotech-derived retinol, a sustainable alternative to synthetically derived retinol.

How can our expanded portfolio support your formulation?

Solus BioTech's portfolio of high purity, naturally derived phosphatidylcholines can support your formulation development across a range of application areas.

Injectable formulations

Our newly expanded portfolio can support a variety of injectable administration routes including intravenous, intramuscular, and subcutaneous through liposomes, emulsions, and suspensions. Furthermore, we have expanded our offering to include parenteral nutrition capabilities that are certified kosher and halal

Oral formulations

we can support your oral delivery needs through emulsifiers, wetting agents, solubilisers and liposomal formations in addition to matrix material for solid dispersions, supporting both slow and fast release tablet formulations

Topical formulations

Phospholipids with a phosphatidylcholine content of ~75% have been extensively used as pharmaceutical emulsifiers and co-emulsifiers. These topical formulations form lamellar layers or micelles on the skin’s surface, protecting the API and allowing it to adhere to the skins surface for longer. In addition, they are highly compatible with cellular membranes and non-irritating, improving patient comfort and compliance

Learn more about our natural phospholipid offering here

Explore related pages:

Croda opens new Global Technical Centre at Genome Valley, Hyderabad, India

PRESS RELEASE – On June 21, 2023, Croda International Plc opened its new Global Technical Centre at Genome Valley, Hyderabad, India.

Croda announces two new partnerships to drive sustainable delivery systems for the pharmaceutical industry

19 May 2023: Croda International Plc (Croda) today announced that it has signed two new partnership agreements that will help the pharmaceutical industry move towards a more sustainable supply chain for vaccine adjuvants.

Croda breaks ground on new manufacturing facility for pharmaceutical excipients in Lamar, Pennsylvania

31st May 2023: Croda, Inc., the company that uses smart science to create high-performance ingredients and solutions that improve lives, broke ground on 9 May 2023, its newest manufacturing facility in Lamar, Clinton County, Pennsylvania.

Published on:

Wednesday 5th July 2023

Please provide an enquiry type

Country